A086460 Stock Overview
Curable. Inc. provides single nucleotide polymorphism (SNP) research and analysis services in South Korea.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Curable. Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩5,250.00 |
52 Week High | ₩10,070.00 |
52 Week Low | ₩3,655.00 |
Beta | 0 |
1 Month Change | 12.66% |
3 Month Change | -12.35% |
1 Year Change | -26.06% |
3 Year Change | -25.43% |
5 Year Change | 9.60% |
Change since IPO | -4.55% |
Recent News & Updates
Recent updates
Shareholder Returns
A086460 | KR Biotechs | KR Market | |
---|---|---|---|
7D | 28.0% | 0.3% | -0.4% |
1Y | -26.1% | 5.7% | 4.5% |
Return vs Industry: A086460 underperformed the KR Biotechs industry which returned 5.7% over the past year.
Return vs Market: A086460 underperformed the KR Market which returned 4.5% over the past year.
Price Volatility
A086460 volatility | |
---|---|
A086460 Average Weekly Movement | 20.8% |
Biotechs Industry Average Movement | 8.4% |
Market Average Movement | 5.2% |
10% most volatile stocks in KR Market | 11.8% |
10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A086460's share price has been volatile over the past 3 months.
Volatility Over Time: A086460's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | n/a | Hyoung-Doo Shin | curablent.com |
Curable. Inc. provides single nucleotide polymorphism (SNP) research and analysis services in South Korea. The company offers various services, such as genome analyzer; and sequencing and re-sequencing, immunoprecipitate sequencing, small RNA discovery and analysis, and digital gene expression profiling services.
Curable. Inc. Fundamentals Summary
A086460 fundamental statistics | |
---|---|
Market cap | ₩15.43b |
Earnings (TTM) | ₩0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A086460 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A086460 income statement (TTM) | |
---|---|
Revenue | ₩0 |
Cost of Revenue | ₩0 |
Gross Profit | ₩0 |
Other Expenses | ₩0 |
Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did A086460 perform over the long term?
See historical performance and comparison